Product Name | AG 1517 |
Description |
EGFR kinase inhibitor |
Purity | >98% (TLC) |
CAS No. | 153436-54-5 |
Molecular Formula | C16H14BrN3O2 |
Molecular Weight | 360.2 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO |
Source | Synthetic |
Appearance | White to off-white solid |
SMILES | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Br)OC.Cl |
InChI | InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20) |
InChIKey | LSPANGZZENHZNJ-UHFFFAOYSA-N |
Safety Phrases |
Classification: Acute toxicity, Oral (Category 3) Skin irritation (Category 2) Serious eye damage (Category 1) Specific target organ toxicity-single exposure (Category 3) Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H301 Toxic if swallowed. H315 Causes skin irritation. H318 Causes serious eye damage. H335 May cause respiratory irritation Precautionary statements: P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P280 Wear protective gloves/ eye protection/ face protection. P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
Cite This Product | AG 1517 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-427) |
Alternative Names | 4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride, AG 1517, PD 153035, SU 5271, ZM 252868, PD 153,035, SU 5271, 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 4705 |
Scientific Background | AG 1517 is a potent and selective ATP competitive inhibitor of the epidermal growth factor receptor tyrosine kinase EGFR. |
References | 1. Kunkel M.W., et al. (1996) Investigational New Drugs. 13(4): 295–302. |
Reviews
There are no reviews yet.